Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study
Само за регистроване кориснике
2018
Аутори
Rosania, RosaVon Arnim, Ulrike
Link, Alexander
Rajilić-Stojanović, Mirjana
Franck, Caspar
Canbay, Ali
Malfertheiner, Peter
Venerito, Marino
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive ...H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.
Кључне речи:
Crohn's disease / ulcerative colitis / Helicobacter pylori / inflammatory bowel diseaseИзвор:
Journal of Gastrointestinal and Liver Diseases, 2018, 27, 2, 119-125Издавач:
- Medical Univ Press, Cluj-Napoca
DOI: 10.15403/jgld.2014.1121.272.hpy
ISSN: 1841-8724
PubMed: 29922755
WoS: 000434805800002
Scopus: 2-s2.0-85049235903
Институција/група
Tehnološko-metalurški fakultetTY - JOUR AU - Rosania, Rosa AU - Von Arnim, Ulrike AU - Link, Alexander AU - Rajilić-Stojanović, Mirjana AU - Franck, Caspar AU - Canbay, Ali AU - Malfertheiner, Peter AU - Venerito, Marino PY - 2018 UR - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/4013 AB - Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded. PB - Medical Univ Press, Cluj-Napoca T2 - Journal of Gastrointestinal and Liver Diseases T1 - Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study EP - 125 IS - 2 SP - 119 VL - 27 DO - 10.15403/jgld.2014.1121.272.hpy ER -
@article{ author = "Rosania, Rosa and Von Arnim, Ulrike and Link, Alexander and Rajilić-Stojanović, Mirjana and Franck, Caspar and Canbay, Ali and Malfertheiner, Peter and Venerito, Marino", year = "2018", abstract = "Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded.", publisher = "Medical Univ Press, Cluj-Napoca", journal = "Journal of Gastrointestinal and Liver Diseases", title = "Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study", pages = "125-119", number = "2", volume = "27", doi = "10.15403/jgld.2014.1121.272.hpy" }
Rosania, R., Von Arnim, U., Link, A., Rajilić-Stojanović, M., Franck, C., Canbay, A., Malfertheiner, P.,& Venerito, M.. (2018). Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study. in Journal of Gastrointestinal and Liver Diseases Medical Univ Press, Cluj-Napoca., 27(2), 119-125. https://doi.org/10.15403/jgld.2014.1121.272.hpy
Rosania R, Von Arnim U, Link A, Rajilić-Stojanović M, Franck C, Canbay A, Malfertheiner P, Venerito M. Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study. in Journal of Gastrointestinal and Liver Diseases. 2018;27(2):119-125. doi:10.15403/jgld.2014.1121.272.hpy .
Rosania, Rosa, Von Arnim, Ulrike, Link, Alexander, Rajilić-Stojanović, Mirjana, Franck, Caspar, Canbay, Ali, Malfertheiner, Peter, Venerito, Marino, "Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study" in Journal of Gastrointestinal and Liver Diseases, 27, no. 2 (2018):119-125, https://doi.org/10.15403/jgld.2014.1121.272.hpy . .